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ABSTRACT
Background: Atopic dermatitis is one of the most common inflammatory skin disorders with increasing prevalence. AD is a multifactorial disease 
influenced by a complex relationship between genetic and environmental factors. Genetic predisposition for atopic diseases may cause an expansion of 
Th2 cells activities, and IL-13 is an important mediator in Th2 immunity response. IL-13 has a role in the abnormal immune response against 
pathogens and decreased skin barrier function, two major predisposing factors for AD. The purpose of this study is to prove that there is a correlation 
between IL-13 serum levels and AD disease severity measured by the SCORAD index. 
Method: This is a cross-sectional analytic observational study. Research subjects are 37 patients with atopic dermatitis and 16 healthy controls. 
Serum samples were processed and analyzed at the GAKI Laboratory of Dr. Kariadi General Hospital Semarang. 
Results: There is a significant difference of IL-13 serum levels between patients with atopic dermatitis and healthy control (p=0.0001), and between 
the study group with mild, moderate and severe atopic dermatitis (p=0.0001). Analysis found a significant and very strong positive correlation 
(p=0.0001; r=0.911) between IL-13 serum levels and SCORAD index. 
Conclusion: There is a significant positive correlation between IL-13 serum levels and atopic dermatitis disease severity, which means that IL-13 
serum level will increase with increasing disease severity of atopic dermatitis.
Key words: IL-13, SCORAD index, atopic dermatitis.
ABSTRAK
Latar belakang: Dermatitis atopik merupakan jenis penyakit inflamasi kulit yang paling sering ditemui dan prevalensinya terus 
mengalami peningkatan. DA bersifat multifaktorial dan dipengaruhi oleh hubungan yang kompleks antara faktor genetik dengan 
lingkungan. Predisposisi genetik untuk penyakit atopi dapat menyebabkan ekspansi aktivitas sel Th2, dan IL-13 merupakan mediator 
penting pada respon imunitas Th2. IL-13 berperan dalam terjadinya kelainan respon imunitas terhadap patogen dan gangguan sawar 
kulit yang merupakan faktor predisposisi utama dari DA. Tujuan penelitian ini adalah membuktikan adanya korelasi antara kadar IL-
13 serum dan derajat keparahan penderita dermatitis atopik yang dinilai dengan SCORAD. 
Metode: Penelitian ini merupakan penelitian analitik observasional dengan pendekatan cross-sectional. Subyek penelitian terdiri atas 37 
orang penderita dermatitis atopik dan 16 orang kontrol sehat. Sampel serum diolah dan diperiksa di Laboratorium GAKI RSUP Dr. 
Kariadi Semarang. 
Hasil: Ditemukan perbedaan kadar IL-13 serum yang bermakna antara pasien dengan dermatitis atopik dan kontrol sehat (p=0,0001), 
serta antar kelompok subyek penelitian dengan dermatitis atopik derajat ringan, sedang dan berat (p=0,0001). Dari uji korelasi 
diperoleh adanya korelasi positif sangat kuat yang bermakna (p=0,0001; r=0,911) antara kadar IL-13 serum dan skor SCORAD. 
Simpulan: Terdapat korelasi positif yang bermakna antara kadar IL-13 serum dan derajat keparahan dermatitis atopik, yang berarti 
bahwa kadar IL-13 serum akan makin meningkat seiring dengan bertambah beratnya derajat keparahan penyakit dermatitis atopik.
Kata kunci: IL-13, skor SCORAD, dermatitis atopik.
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may induce dermal inflammation and remodeling 
17in transgenic mice with AD.  Another study also 
found that IL-13 is a potent mediator for pathologic 
fibrosis in AD,20 and IL-13 may induce AD and 
atopic march through a TSLP-dependent 
21mechanism.  Another study in Italy found a 
dominant Th2 profile in the blood of children with 
AD, and IL-13 is correlated with AD disease 
22severity.  These studies showed that IL-13 levels is 
correlated with the disease activity of atopic 
dermatitis.
Studies assessing the relationship between IL-13 
serum levels and AD disease severity measured by 
SCORAD index are lacking. This encourages us to 
do a research on this topic.
MATERIALS AND METHOD
This is a cross-sectional analytic observational 
study. Research subjects are 37 patients with atopic 
dermatitis treated at the dermatology and 
venereology clinic of Dr. Kariadi General Hospital 
Semarang that met the inclusion criteria and 16 
healthy controls. Subjects are selected using the 
consecutive sampling method from January 2015 to 
March 2015.
Atopic dermatitis disease severity was assessed 
using the Scoring for Atopic Dermatitis (SCORAD) 
index. The score is calculated based on the intensity 
of eczematous lesion such as redness, swelling, 
oozing, scratch marks, lichenification (skin 
thickening), and skin dryness (assessed in area 
where there is no inflammation) in nine body areas 
(rule of nine). Subjective symptoms such as itch and 
sleeplessness will also be assessed. Higher score 
showed more severe atopic dermatitis.
Venous blood sample were taken from every 
subject to analyze the IL-13 serum levels. This 
analysis was done using ELISA IL-13 examination 
kit from R&D Quantikine® at GAKI Laboratory of 
Dr. Kariadi General Hospital Semarang. This study 
has been approved by the ethic committee of 
Faculty of Medicine Diponegoro University / Dr. 
Kariadi General Hospital Semarang.   
Statistical analysis was done using Statistical 
Programs for Social Science (SPSS) 15.0. The 
correlation between IL-13 serum levels and 
SCORAD index is considered significant when 
p<0.05 and the correlation coefficient (r) is close to 
+1.  
PENDAHULUAN
Atopic dermatit is  (AD) is  a  chronic 
inflammatory skin disorders characterized by 
erythematous and pruritic skin lesions with 
excoriation in the acute stage and lichenification in 
the chronic stage. Patients with this disorder may 
also have asthma and allergic rhinitis as part of the 
 1-7atopic march.  
Atopic dermatitis is one of the most common 
inflammatory skin disorders and can be found in 
8-1010–20% children and 1–3% adults globally.  The 
4,11prevalence of AD has increased in the last decade.  
There were 1261 patients with AD at the 
dermatology and venereology clinic of Dr. Kariadi 
General Hospital Semarang between 1996–2000, 
where 770 were new cases. Of all pediatric patients, 
the highest incidence was found in the less than 5 
years old age group (62.6%; 123/197), followed by 
125–14 years old (37.4%; 74/197).  Based on the 
recapitulation done by the Pediatric Dermatology 
Study Group (KSDAI) in five largest cities in 
Indonesia in 2000, AD was the most common 
(23.67%) pediatric skin disorders in ten largest 
hospitals from these cities. In 2005, AD was 36% of 
13all dermatitis cases in Indonesia.
The pathogenesis and etiology of AD is not fully 
understood, however this disease is likely 
multifactorial and may be influenced by a complex 
relationship between genetic and environmental 
5,8,11,14factors.  The genetic predisposition for atopic 
disorders may cause an expansion in Th2 cells 
activities, and will increase the secretion of 
Interleukin-5 (IL-5), IL-4, IL-13, IL-3, IgE, mast cells 
15and cause eosinophilia.  There is a correlation 
between immune disorders and decreased 
epidermal barrier function in AD, which means that 
several cytokines that play a role in AD, such as IL-4, 
IL-13 and IL-22, may inhibit the production of skin 
5barrier protein (FLG and LOR).
The effects of Interleukin 13 on the Th2 
inflammation may play an important role in asthma 
and AD. These effects are the ability to induce IgE 
production, CD23 expression, endothelial P-selectin 
and vascular cell adhesion molecule-1 expression, 
16and to inhibit eosinophil apoptosis.  IL-13 also 
reduce the expression of antimicrobial peptide in 
eczematous skin, which will make the skin more 
17-19prone to recurrent infections.
A study in the United States found that IL-13 
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subjects are between 10.5–53.4 (mean ± SD, 30.82 ± 
13.96). Subject with mild atopic dermatitis has mean 
SCORAD index of 17.23 ± 3.56, moderate 36.95 ± 
6.96, and severe 51.82 ± 1.12 (Table 2). Based on the 
SCORAD index, there are 16 (43.3%) subjects with 
mild atopic dermatitis, 15 (40.5%) with moderate 
atopic dermatitis, and 6 (16.2%) with severe atopic 
dermatitis.
Mean IL-13 serum level in this study is 12.38 
pg/mL for patients with atopic dermatitis and 2.55 
pg/mL for healthy control. Analysis found a 
significant difference between mean IL-13 serum 
levels in patients with atopic dermatitis and healthy 
control (p=0.0001). (Table 3).
In this study, IL-13 serum level in patients with 
atopic dermatitis is between 3.67 pg/mL to 30.00 
pg/mL (mean ± SD, 12.38 ± 7.19). Subjects with mild 
atopic dermatitis had IL-13 serum level between 
3.67–9.64 pg/mL (mean ± SD, 6.51 ± 2.03), moderate 
between 10.09–19.80 pg/mL (mean ± SD, 13.31 ± 
2.68), and severe between 11.01  30.00 pg/mL (mean 
± SD, 21.57 ± 7.08)  (Table 4). 
The data normality for IL-13 level was analyzed 
using Saphiro-Wilk test. Because the data showed 
normal distribution, we analyze the difference of 
mean IL-13 serum levels between AD disease 
severity groups using One-way ANOVA test. The 
test showed p value of 0.0001. Because p < 0.05 then 
we concluded that there is a significant difference in 
IL-13 serum levels between study subjects with 
mild, moderate and severe atopic dermatitis. 
RESULTS
This study obtained 37 subjects with atopic 
dermatitis (AD) that met the inclusion criteria with 
the age between 16 to 86 years old (mean ± SD, 38.57 
± 20.26 years old). Seventeen (45.9%) subjects are 
male and 20 (54.1%) female. Highest level of 
education for most subjects are graduate degree 
(51.4%), and the most frequent occupation are 
college student (35.1%) and private employee 
(32.4%). Subjects in this study shoved varied 
duration of disease, between 0.5 to 50 years (mean ± 
SD, 14.27 ± 12.78) (Table 1).
Among the 37 study subjects, 21 (56.75%) has 
history of atopic disease other than atopic 
dermatitis, mostly allergic rhinitis in 12 (32.4%) 
subjects, and asthma, conjunctivitis and urticaria in 
4 (10.8%), 4 (10.8%), and 8 (21.6%, respectively. The 
most common precipitating factors causing 
recurrence of atopic dermatitis are cold weather 
(56.8%), shrimp (27.0%), dust (27.0%), stress 
(24.3%), and fish (16.2%). There are no significant 
correlation between precipitating factors of atopic 
dermatitis and disease severity measured by the 
SCORAD index. The SCORAD index from 37 study 
Tabel 1. The characteristic of study subjects 
Characteristic
Age (year)
Sex
n (%)
Male 17 (45.9%)
Mean ± SD
38.57 ± 20.26
Female 20 (54.1%)
Education
Elementary school
Junior high school
Senior high school
Academy
Graduate
Post-graduate
Occupation
Student
College student
Private employee
Entrepreneur
Driver
Retired
Not working
Onset (year)
Duration of disease (year)
2 (5.4%)
6 (16.2%)
7 (18.9%)
2 (5.4%)
19 (51.4%)
1 (2.7%)
2 (5.4%)
13 (35.1%)
12 (32.4%)
5 (13.5%)
2 (5.4%)
1 (2.7%)
2 (5.4%)
24.74 ± 19.73
14.27 ± 12.78
Tabel 2.  The result of SCORAD index assessment 
Study subject
All subject (n=37)
Mild AD (n=16)
Moderate AD (n=15)
SCORAD index
10,5–23,4
10,5–53,4
27,6–48,6
Min-max Mean ± SD
17,23 ± 3,56
30,82 ± 13,96
36,95 ± 6,96
Severe AD (n=6) 50,4–53,4 51,82 ± 1,12
Tabel 3.  Mean IL-13 serum levels in study subjects
Study subject
Atopic dermatitis
   patients (n=37)
Healthy control (n=16)
Mean IL-13
serum levels
2,55 ± 1,31
12,38 ± 7,19 0,0001*
p value
*Mann Whitney test
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11adult onset.  Along with the increasing prevalence 
of AD for the last decades, the prevalence for adult 
onset AD was also increased to 1–3% in several 
25countries.  Prevalence of AD in these countries may 
be influenced by race, genetic, and geographic 
23factors.  In this study, the age of the study subjects 
are between 16 to 86 years old. 
The etiology if AD is not fully understood, but 
there are several factors that may play a role in AD, 
such as food allergen, aeroallergen, autoallergen, 
26skin infection, or stress.  In this study, the most 
common precipitating factors causing recurrence of 
atopic dermatitis are cold weather (56.8%), shrimp 
(27.0%), dust (27.0%), stress (24.3%), and fish 
(16.2%). 
A study found that 83% AD patients reported 
cold weather as a precipitating factor. Cold weather 
may reduce air humidity, thus making the skin dry 
27and inducing pruritus.  Exacerbation of AD was 
also reported in patients with house dust mite 
exposure. Epicutaneous aeroallergen (such as house 
dust mite, grass, animal dander, and fungus) given 
using atopic skin prick test may induce eczematoid 
reaction in 30–50% patients with AD. Study found 
that an effective measures to reduce house dust mite 
exposure may reduce AD symptoms. The degree of 
IgE sensititation is directly proportional to AD 
28disease severity.
Food that often become a precipitating factor for 
atopic disease (asthma, allergic rhinitis, atopic 
dermatitis) in adults are seafood, especially shrimp, 
29lobster, crab, and fish.  Aside from cold weather, 
food and dust, psychological stress is also an 
important precipitating factor that may induce an 
exacerbation of AD. Stress may cause disturbance in 
hypothalamus-pituitary-adrenal axis and blocking 
Corticotropin Releasing Factor (CRF), which in 
return will reduce Th1 activity and push the 
30Th1/Th2 balance toward Th2.  This study found no 
Post Hoc test was used to analyze the difference 
of mean IL-13 serum levels between two subject 
groups based on AD disease severity. This analysis 
showed a significant difference in mean IL-13 serum 
level between study subjects with mild and 
moderate AD (p=0.0001), mild and severe AD 
(p=0.0001), and moderate and severe AD (p=0.005) 
(Table 5).
Normality test for IL-13 serum levels and 
SCORAD index showed data with abnormal 
distribution, thus Spearman test was used to 
analyze the correlation between these variables. 
Analysis found a significant and very strong 
positive correlation (p=0.0001; r=0.911) between IL-
13 serum levels and SCORAD index.
DISCUSSION
The study subjects consisted of 17 male and 20 
female patients with atopic dermatitis with varied 
duration of disease, but most of them have had this 
disease for more than 1 year. Atopic dermatitis (AD) 
is a chronic inflammatory skin disorder with 
3,6,7frequent recurrence or remission.  Studies from 
several countries have found equal incidence of AD 
23,24in male and female patients.
Atopic dermatitis usually manifested in infancy 
(45% case showed onset during the first 6 month 
after birth), and 70% children had this disease before 
the age of 5. Atopic dermatitis may also have an 
Tabel 4.  IL-13 serum levels based on AD disease severity
Control group
Study subjects IL-13 serum levels
2,55 ± 1,31 
Mean ± SD Median Minimum Maximum
2,75 0,46 4,59
Mild AD (n=16)
Moderate AD (n=15)
Severe AD (n=6)
Total subject (n=37)
6,51 ± 2,03
13,31 ± 2,68
21,57 ± 7,08
12,38 ± 7,19
6,42
13,08
20,40
11,01
3,67
10,09
11,01
3,67
9,64
19,80
30,00
30,00
Tabel 5.  Differences of IL-13 serum level between study subjects
Study subjects
Mild AD (n=16)
Moderate AD (n=15)
Moderate AD
(n=15)
–
0.0001* 0.0001*
Severe AD
(n=6)
*Post Hoc test
0.005*
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This study found a significant difference in 
mean IL-13 serum levels between study subjects 
with mild, moderate and severe atopic dermatitis. 
We also found a significant positive correlation 
between IL-13 serum levels and AD disease severity 
measured by SCORAD index. A previous study in 
an outpatient clinic in Italy also observed similar 
results. They found a significant relationship 
between CD4+IL-13+ levels with AD disease 
severity measured by SCORAD index. These cells is 
considered as an excellent biologic marker for atopic 
dermatitis because we can observe a dynamic 
changes in CD4+IL-13+ levels with AD disease 
22progression.  Another study in Egypt assessing IL-
13 levels in AD patients before and after topical 
treatment also found a significant correlation 
between the levels of this cytokine and disease 
severity measured by SCORAD index. They 
observed a significant decrease in IL-13 levels after 
38treatment.
The results of this study in conjunction with the 
previous studies described above showed that IL-13 
plays a role in decreased skin barrier function and 
chronic inflammation through several cellular or 
molecular mechanism thus considered to also play 
an important role in the pathogenesis of AD and as a 
17,36potential therapeutic target for AD in the future.  
Treatment using topical IL-13 antisense 
oligonucleotide with cationic elastic liposome (IL-13 
ASO/cEL complex) in mice was reported to reduce 
clinical symptoms of AD, thus this formulation is 
considered a potential therapeutic tool for the 
39treatment of AD in human.  There are several anti-
interleukin 13 drugs developed for the treatment of 
AD in human, such as Dupilumab, Lebrikizumab, 
and Pitrakinra, which currently being tested in a 
40,41,42phase II/III trials with promising results.
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